SCHEMBL4575595

SCHEMBL4575595

COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1OCC(O)CO

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 7/20 0.73
CYP1A1 P04798 6/20 0.67
CYP1A2 P05177 6/20 0.67
IP6K2 Q9UHH9 5/20 0.67
MEN1 O00255 4/20 0.67
ALDH1A1 P00352 4/20 0.67
MAPT P10636 4/20 0.67
KMT2A Q03164 4/20 0.67
HDAC6 Q9UBN7 4/20 0.67
ABCC1 P33527 3/20 0.67
XDH P47989 3/20 0.67
IPMK Q8NFU5 3/20 0.67
POLB P06746 2/20 0.67
KDM1A O60341 1/20 0.67
MAOA P21397 4/20 0.60
AKR1B1 P15121 3/20 0.60
MAPK8 P45983 1/20 0.60
MAOB P27338 4/20 0.57
FLT3 P36888 4/20 0.57
LMNA P02545 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4574696 0.94 CYP1B1 (0.64) CYP1B1CYP1A1CYP1A2IP6K2MEN1
SCHEMBL8306291 0.91 CYP1B1 (0.68) CYP1B1CYP1A1CYP1A2IP6K2MEN1
SCHEMBL8305042 0.88 CYP1B1 (0.58) CYP1B1CYP1A1CYP1A2IP6K2MEN1
SCHEMBL8431111 0.87 CYP1B1 (0.57) CYP1B1CYP1A1CYP1A2IP6K2MEN1
SCHEMBL4575622 0.87 CYP1B1 (0.68) CYP1B1CYP1A1CYP1A2IP6K2MEN1
SCHEMBL8304881 0.87 CYP1B1 (0.68) CYP1B1CYP1A1CYP1A2IP6K2MEN1
SCHEMBL4575616 0.87 CYP1B1 (0.68) CYP1B1CYP1A1CYP1A2IP6K2MEN1
SCHEMBL30365934 0.85 CYP1B1 (1.00) CYP1B1CYP1A1CYP1A2IP6K2MEN1
SCHEMBL29883103 0.85 CYP1B1 (1.00) CYP1B1CYP1A1CYP1A2IP6K2MEN1
SCHEMBL2483636 0.85 CYP1B1 (1.00) CYP1B1CYP1A1CYP1A2IP6K2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176934-A1 Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies LES LABORATOIRES SERVIER (FR) 2008-07-24 US disclosed
US-20080176934-A1 Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies LES LABORATOIRES SERVIER (FR) 2008-07-24 US disclosed
US-20080176934-A1 Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies LES LABORATOIRES SERVIER (FR) 2008-07-24 US disclosed
EP-0709383-B1 Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1999-12-15 EP disclosed
US-5629339-A CHRONIC VENOUS INSUFFICIENCY ADIR ET COMPAGNIE (FR) 1997-05-13 US disclosed
EP-0709383-A1 Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1996-05-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176934-A1 Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies ADAMTS13, ADAMTS1, SERPINC1 CYP1B1 340/4885CYP1A1 545/4885CYP1A2 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.